Glucosamine arthritis treatment

[ad]

How Glucosamine works on arthritis:

Glucosamine sulfate is a natural substance that can be found around the cartilage cells. Glucosamine is actually an amino sugar that the body synthesizes and then distributes it to connective tissues. The body produces an exact amount of glucosamine which is used for the maintenance of healthy joints. As we grow older, the body loses its ability to produce enough glucosamine to maintain very good joint health. Current research shows that glucosamine may slow down the progression of arthritis by keeping the joint cartilage healthy. It also helps in easing the pain caused by osteoarthritis, rehabilitation of cartilage, joint repair, stimulation of proteoglycans and glycosaminoglycans, and renewal of synovial fluid.

Side Effects and Precautions of Glucosamine:

Glucosamine is fairly safe and does not carry the worrying side effects of NSAIDs. Some people may experience stomach cramps or loose stools.
[ad]

Forms, Dosage and Brand Names of Glucosamine:

Adults: 1,500 mg a day given as 500 mg tablets or capsules three times a day.

Pregnant Women: It is best not to take glucosamine until more is known about the effects of this supplement.

Children: Not recommended

References about Glucosamine and Arthritis:

Reginster JY, Gillot V, Bruyere O, Henrotin Y. Evidence of nutriceutical effectiveness in the treatment of osteoarthritis. Curr Rheumatol Rep 2000; 2: 472-77.

Constantz RB. Hyaluronan, glucosamine and chondroitin sulfate: roles for therapy in arthritis? In: Kelley WN, Harris ED, Ruddy S, Sledge CB, eds. Textbook of rheumatology. Philadelphia: WB Saunders, 1998.

Deal CL, Moskowitz RW. Nutraceuticals as therapeutic agents in osteoarthritis: the role of glucosamine, chondroitin sulfate, and collagen hydrolysate. Rheum Dis Clin North Am 1999; 25: 379-95.

McAlindon TE, LaValley MP, Gulin JP, Felson DT. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA 2000; 283: 1469-75.

Comments are closed.